| Ytd | -69.79% | |
| 1y | -79.63% |
| Open | 3.65 | Prev Close | 3.87 | Low | 3.62 | High | 3.94 | Mkt Cap | 9.36M |
| Vol | 96.53K | Avg Vol | 159.31K | EPS | -1.93 | P/E | -2.00 | Forward P/E | -0.52 |
| Beta | 1.43 | Short Ratio | 0.98 | Inst. Own | 11.39% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 03-04 | 50-d Avg | 4.30 | 200-d Avg | 7.84 | 1yr Est | 15.75 |
PSTV News
Shares of Plus Therapeutics, Inc. (NASDAQ: PSTV - Get Free Report) have been given a consensus recom
HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), t
HOUSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a
CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("P
HOUSTON, July 21, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Pl
The collaboration is expected to enable comprehensive DNA and RNA profiling across hundreds of clini
Collaboration expected to deliver hundreds of DNA and RNA biomarkers from a single CSF specimen — di
Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), today highlighted t
Updated NCCN language continues to support CSF analysis in the diagnosis and management of leptomeni
Plus Therapeutics, Inc. (PSTV) Discusses Rebranding and Integrated CNS Oncology Platform Strategy Tr
Plus Therapeutics to become Cerenome, to trade under new Nasdaq ticker CNSY on August 3, 2026 Affirm
CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("P
HOUSTON, June 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plu
Management to update on 2026 mid-year progress, milestones and provide details on its integrated CNS
Top analysts changed their views on top stocks. For all changes, upgrades and downgrades, see analys
Plus Therapeutics Inc (NASDAQ:PSTV) said its CNSide Diagnostics unit has received accreditation from
Plus Therapeutics Inc (NASDAQ:PSTV) said its CNSide Diagnostics unit has received accreditation from
HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plu
Plus and Harvard analysis shows CNSide enables early diagnosis and better clinical decision-making
Partnership to deliver a novel AI-native integrated CNS oncology platform Platform will unify and an
Plus Therapeutics (PSTV) came out with a quarterly loss of $1.05 per share versus the Zacks Consensu
HOUSTON, May 15, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Com
CNS Pharmaceuticals (NASDAQ:CNSP) is back on every biotech watchlist after a 242.36% one-week ramp t
Plenary session at AANS underscores REYOBIQ's potential as a differentiated targeted radiotherapeuti
Top Wall Street analysts changed outlook on top names. Needham downgrades CNTA, Baird downgrades PHR
Benzinga examined the prospects for many investors' favorite stocks over the last week — here
US stock futures down, investors focus on Sify, Boot Barn, Wealthfront, Plus Therapeutics, Solowin;
Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday'
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announce
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on T
Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The
U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 1% on Thursday.
Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session.
